Recombinant soluble thrombomodulin for postoperative disseminated intravascular coagulation.

[1]  N. Tomita,et al.  A Pancreaticoduodenectomy Risk Model Derived From 8575 Cases From a National Single-Race Population (Japanese) Using a Web-Based Data Entry System: The 30-Day and In-hospital Mortality Rates for Pancreaticoduodenectomy , 2014, Annals of surgery.

[2]  山川 一馬,et al.  Clinical evaluation of recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation , 2014 .

[3]  N. Tomita,et al.  Risk stratification of 7,732 hepatectomy cases in 2011 from the National Clinical Database for Japan. , 2014, Journal of the American College of Surgeons.

[4]  G. Clarke,et al.  Patients with faecal peritonitis admitted to European intensive care units: an epidemiological survey of the GenOSept cohort , 2014, Intensive Care Medicine.

[5]  M. Boermeester,et al.  A decision rule to aid selection of patients with abdominal sepsis requiring a relaparotomy , 2013, BMC Surgery.

[6]  J. Mimuro,et al.  Impact of recombinant soluble thrombomodulin (thrombomodulin alfa) on disseminated intravascular coagulation. , 2013, Thrombosis research.

[7]  T. Shimazu,et al.  Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis , 2013, Intensive Care Medicine.

[8]  M. Di Nisio,et al.  Diagnosis and treatment of disseminated intravascular coagulation: guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). , 2012, Thrombosis research.

[9]  S. Kim,et al.  The Clinical Factors for Predicting Severe Diverticulitis in Korea: A Comparison with Western Countries , 2012, Gut and liver.

[10]  I. Maruyama,et al.  THROMBOMODULIN ALFA IN THE TREATMENT OF INFECTIOUS PATIENTS COMPLICATED BY DISSEMINATED INTRAVASCULAR COAGULATION: SUBANALYSIS FROM THE PHASE 3 TRIAL , 2011, Shock.

[11]  T. van der Poll,et al.  Inflammation and coagulation , 2010, Critical care medicine.

[12]  J. Thachil,et al.  Guidelines for the diagnosis and management of disseminated intravascular coagulation , 2009, British journal of haematology.

[13]  S. Yamada,et al.  Proteolytic Cleavage of High Mobility Group Box 1 Protein by Thrombin–Thrombomodulin Complexes , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[14]  N. Aoki,et al.  Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double‐blind clinical trial , 2007, Journal of thrombosis and haemostasis : JTH.

[15]  C. Esmon.  The interactions between inflammation and coagulation , 2005, British journal of haematology.

[16]  Hiroshi Yamamoto,et al.  The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. , 2005, The Journal of clinical investigation.

[17]  C. Toh,et al.  Disseminated intravascular coagulation: old disease, new hope , 2003, BMJ : British Medical Journal.

[18]  B. Gathof,et al.  Re-operation for complicated secondary peritonitis - how to identify patients at risk for persistent sepsis. , 2003, European journal of medical research.

[19]  L. Díaz-Flores,et al.  [Disseminated intravascular coagulation]. , 1977, Actas dermo-sifiliograficas.

[20]  S. Lewis,et al.  British Committee for Standards in Haematology , 1969 .

[21]  S. Lewis.  British Committee for Standards in Haematology , 1969 .

[22]  S. Madoiwa,et al.  Expert consensus for the treatment of disseminated intravascular coagulation in Japan. , 2010, Thrombosis research.